Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
AstraZeneca
Daiichi Sankyo
Deloitte
Moodys
McKesson
Cantor Fitzgerald
Novartis
Express Scripts

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,887,845

« Back to Dashboard

Which drugs does patent 7,887,845 protect, and when does it expire?


Patent 7,887,845 protects INTELENCE and is included in one NDA.

This patent has seventy-eight patent family members in thirty-six countries.

Summary for Patent: 7,887,845

Title:Antiviral compositions
Abstract:The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture.
Inventor(s): Verreck; Geert (Malle, BE), Baert; Lieven (Brugge 2, BE)
Assignee: Janssen Pharmaceutica NV (BE)
Application Number:11/347,071
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-003Mar 26, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-001Jan 18, 2008RXYesNo► Subscribe► Subscribe► SubscribeY
Janssen R And DINTELENCEetravirineTABLET;ORAL022187-002Dec 22, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,887,845

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99203128Sep 24, 1999

Non-Orange Book Patents for Patent: 7,887,845

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,638,932 2,4-disubstituted triazine derivatives► Subscribe
7,241,458Antiviral compositions► Subscribe
7,015,2212,4-disubstituted triazine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,887,845

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
MexicoPA02003182► Subscribe
South Korea100820605► Subscribe
Japan2002529457► Subscribe
South Korea20070036805► Subscribe
Israel143024► Subscribe
Israel148801► Subscribe
Indonesia28545► Subscribe
Hungary0104395► Subscribe
Hungary228449► Subscribe
Hungary0203568► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Novartis
Fish and Richardson
Deloitte
Boehringer Ingelheim
Merck
US Department of Justice
Farmers Insurance
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot